Intervention Review

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

  1. Lorna Gibson2,
  2. David Lawrence3,
  3. Claire Dawson1,
  4. Judith Bliss1,*

Editorial Group: Cochrane Breast Cancer Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 29 JUN 2008

DOI: 10.1002/14651858.CD003370.pub3

How to Cite

Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD003370. DOI: 10.1002/14651858.CD003370.pub3.

Author Information

  1. 1

    The Institute of Cancer Research, Clinical Trials and Statistics Unit, Sutton, Surrey, UK

  2. 2

    London School of Hygiene and Tropical Medicine, Cancer and Public Health Unit, London, Greater London, UK

  3. 3

    Cancer Research UK and UCL Cancer Trials Centre, London, UK

*Judith Bliss, Clinical Trials and Statistics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 OCT 2009


Cited in:


This article has been cited by:

  1. 1
    C. Koopal, M.L. Janssen-Heijnen, A.J. van de Wouw, J.P. van den Bergh, Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer, The Breast, 2015, 24, 2, 153


  2. 2
    E. Kelly, C. Y. Lu, S. Albertini, A. Vitry, Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison, Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 1
  3. 3
    D.M. Layfield, M. Mohamud, O. Odofin, C. Walsh, G.T. Royle, R.I. Cutress, Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma, The Surgeon, 2015, 13, 2, 61


  4. 4
    Elsa Dalmau, Alejandra Armengol-Alonso, Montserrat Muñoz, Miguel Ángel Seguí-Palmer, Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer, The Breast, 2014, 23, 6, 710


  5. 5
    C.A. DeNysschen, H. Burton, F. Ademuyiwa, E. Levine, S. Tetewsky, T. O'Connor, Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study, European Journal of Cancer Care, 2014, 23, 4
  6. 6
    Hannah S. van Meurs, Luc R.C.W. van Lonkhuijzen, Jacqueline Limpens, Jacobus van der Velden, Marrije R. Buist, Hormone therapy in ovarian granulosa cell tumors: A systematic review, Gynecologic Oncology, 2014, 134, 1, 196


  7. 7
    Jonathan F. Russell, Jenise C. Wong, Melvin M. Grumbach, Genetic Steroid Disorders, 2014,


  8. 8
    Hans Wouters, Erica C.G. van Geffen, Monique C. Baas-Thijssen, Elly M. Krol-Warmerdam, Anne M. Stiggelbout, Svetlana Belitser, Marcel L. Bouvy, Liset van Dijk, Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: Nature and relevance for non-adherence, The Breast, 2013, 22, 5, 661


  9. 9
    Caroline D. Lynch, Men-Jean Lee, Giuseppe Del Priore, Clinical Pharmacology During Pregnancy, 2013,


  10. 10
    Ewa Mrózek, Rachel Layman, Bhuvaneswari Ramaswamy, Larry Schaaf, Xiaobai Li, Susan Ottman, Charles L. Shapiro, Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer, Clinical Breast Cancer, 2012, 12, 2, 151


  11. 11
    Daniel Hanratty, Helen Sweetland, Role of endocrine therapy in cancer treatment, Surgery (Oxford), 2012, 30, 4, 194


  12. 12
    R.E. Coleman, G. Bertelli, T. Beaumont, I. Kunkler, D. Miles, P.D. Simmonds, A.L. Jones, I.E. Smith, UK Guidance Document: Treatment of Metastatic Breast Cancer, Clinical Oncology, 2012, 24, 3, 169


  13. 13
    M. Beresford, I. Tumur, J. Chakrabarti, J. Barden, N. Rao, A. Makris, A Qualitative Systematic Review of the Evidence Base for Non-cross-resistance between Steroidal and Non-steroidal Aromatase Inhibitors in Metastatic Breast Cancer, Clinical Oncology, 2011, 23, 3, 209


  14. 14
    Vivian Chi Yan Lee, William Ledger, Aromatase inhibitors for ovulation induction and ovarian stimulation, Clinical Endocrinology, 2011, 74, 5
  15. 15
    Mario Giuliano, Rachel Schiff, C. Kent Osborne, Meghana V. Trivedi, Biological mechanisms and clinical implications of endocrine resistance in breast cancer, The Breast, 2011, 20, S42


  16. 16
    Jan Oldenburg, Cecilie Kiserud, Henriette Magelssen, Marianne Brydøy, Sophie D. Fosså, Supportive Oncology, 2011,


  17. 17
    Julia A. Files, Marcia G. Ko, Sandhya Pruthi, Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists, Mayo Clinic Proceedings, 2010, 85, 6, 560


  18. 18
    Xiaoshu Zhu, Alan Bensoussan, Ewan D McNicol, Hongfeng Chen, Weidong Lu, Acupuncture for treatment-related side effects in women with breast cancer, The Cochrane Library,
  19. 19
    Anil Roy, Timothy J Schultz, Kristin V Carson, Brian J Smith, Heather Powell, Amanda Wilson, E. Haydn Walters, Asthma self management education with either regular healthcare professional review or written action plans or both in adults, The Cochrane Library,